Loading organizations...
§ Private Profile · Kansas City, MO, USA
Trially is a technology company.
Trially is an artificial intelligence and data science firm developing an AI-native platform specifically designed to streamline clinical trial recruitment. This platform utilizes HIPAA-compliant Large Language Model agents to accurately match, engage, and enroll eligible patients into clinical trials. The technical approach centers on leveraging patient data and integrating seamlessly with existing electronic health records, clinical trial management systems, and customer relationship management platforms to prescreen candidates.
The company was co-founded by Kyle McAllister, CEO, Ramon Prieto, CTO, and Trevor Welch, CPO. McAllister, an industry veteran, identified significant inefficiencies and delays in clinical trial patient enrollment. Prieto, a former Senior AI/ML Engineer from Zapier, brings expertise in re-architecting data infrastructure, while Welch, also formerly of Zapier and an AI/NLP expert, contributes product leadership. Their collective insight highlighted that untapped patient data could significantly accelerate trial progress.
Trially serves a diverse clientele including pharmaceutical sponsors, contract research organizations, clinical research sites, and hospitals. Its offerings aim to enhance overall enrollment rates, minimize screen failures, and improve patient identification processes. The company’s long-term vision is to expedite the delivery of crucial treatments to patients by enabling more insightful and efficient work for clinical professionals, ensuring that trial-ready candidates connect with therapies faster.
Trially has raised $5.0M across 1 funding round.
Trially has raised $5.0M in total across 1 funding round.
Trially has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Seed in September 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2025 | $5M Seed | Flyover Capital | High Alpha, Alpaca VC, Atria Ventures, BLU Ventures, Gaingels, Looking Glass Capital, Redbud VC, The Council | Announced |
Trially has raised $5.0M in total across 1 funding round.
Trially's investors include Flyover Capital, High Alpha, Alpaca VC, Atria Ventures, Blu Ventures, Gaingels, Looking Glass Capital, Redbud VC, The Council.
Trially is an AI-powered platform that automates patient identification, matching, and enrollment for clinical trials by integrating with electronic health records (EHRs), clinical trial management systems (CTMS), and customer relationship management (CRM) tools.[1][2][6] It serves research sites, hospitals, sponsors, contract research organizations (CROs), and providers, solving the core problem of trial delays—86% of trials face recruitment bottlenecks, costing sponsors over $600K daily and sites 250+ hours monthly on manual chart reviews—by delivering ~95% screening accuracy, 2-6x more enrollments in complex studies, and real-time protocol analysis.[1][2][4][5][6] Founded in 2023 in Kansas City, Missouri, Trially recently raised $4.7M in seed funding led by Flyover Capital and launched its agentic AI solution, Margo, to convert matches into enrollments via HIPAA-compliant large language models (LLMs).[3][4]
Trially was founded in 2023 by CEO Kyle McAllister, CTO Ramon Prieto, and Trevor Welch in Kansas City, Missouri.[1][2][3] McAllister, an industry veteran and entrepreneur with successful exits, drew from personal experience with customer pain points in clinical trials, while Prieto (ex-Zapier, where he re-architected its $5B data infrastructure) and Welch brought machine learning and AI expertise from Zapier.[3][5] The idea emerged to address inefficiencies in patient recruitment, such as manual EHR reviews and high screen failures; early traction came from integrations with sites like ClinTrial Research, boosting KPIs across therapy areas like CNS and oncology.[1][3] Pivotal moments include a $4.7M seed round in 2025 (with investors like Atria and Gaingels) and hiring serial entrepreneur Christian Smith as CRO.[3][4]
Trially rides the AI-in-healthcare wave, specifically agentic AI and LLMs for unstructured clinical data, amid a $50B+ clinical trials market plagued by recruitment delays that inflate costs and slow therapies.[4][5] Timing aligns with post-pandemic trial acceleration demands, EHR digitization, and regulatory pushes for diversity/efficiency; market forces like pharma's daily losses and sites' manual burdens favor scalable AI over ads.[1][3][5] It influences the ecosystem by bridging sites, sponsors, and health systems—potentially expanding to physician-led trial discovery—positioning Trially as a leader in unlocking "untapped patient data" for faster drug development.[3][5]
Trially's seed funding and Margo launch signal rapid scaling across CROs, pharma, and physician networks, with plans to mesh site and health system sides for mega-opportunities in trial discovery.[3][4] Trends like multimodal AI, real-world evidence integration, and decentralized trials will amplify its edge, potentially evolving into a full-stack enrollment platform amid rising AI adoption in life sciences. As the bridge from protocol to patient, Trially could redefine trial speed, delivering therapies faster while commanding premium site/sponsor adoption.[1][3][4]